Entities / Company
Merck Sharp & Dohme.
company in Madrid, Spain
- Reports this week
- 0
- Active events
- 0
- Connections
- 16
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.Well supported3 reports
-
Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.Some support1 report
-
TD Cowen maintained a Hold rating on Merck Sharp & Dohme on July 4, 2025.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 16, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Glenmark Pharmaceuticals Operational
The two companies are in direct market competition, evidenced by Glenmark launching a drug equivalent to Merck's BRIDION.
History
Events by the month they beganJuly 2026
1 eventJune 2026
3 events- Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.
- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- TD Cowen maintained a Hold rating on Merck Sharp & Dohme on July 4, 2025.